Basic Information



Gene symbol TERT Synonyms CMM9, DKCA2, DKCB4, EST2, PFBMFT1, TCS1, TP2, TRT, hEST2, hTRT Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas | PertOrg
Description telomerase reverse transcriptase

GTO ID GTC3974
Trial ID NCT04685499
Disease Head and Neck Squamous Cell Carcinoma
Altered gene E1A|E1B|TERT
Therapeutic/Target gene Therapeutic gene
TherapyDNA oncolytic virus
Treatment Telomelysin|OBP-301
Co-treatment pembrolizumab
PhasePhase2
Recruitment statusTerminated
TitlePhase 2 Study of OBP-301 (Telomelysin ™) in Combination With Pembrolizumab and Stereotactic Body Irradiation in Patients With Head and Neck Squamous Cell Carcinoma With Inoperable, Recurrent or Progressive Disease
Year2021
CountryUnited States
Company sponsorWeill Medical College of Cornell University
Other ID(s)19-12021148
Vector information
Vectoradenovirus
ConstructAd5-hTERT-E1A-IRES-E1B
Vector typea first generation, replication-defective adenovirus serotype 5 (Ad5) vector
Transgene/Inserted genehTERT, which can be utilized as a molecular switch for the selective expression of target genes in tumor cells.
Regulatory elementa human telomerase reverse transcriptase gene (hTERT) promoter

Clinical Result

Cohort 1
Administration route intratumoral injection
Dosage Telomelysin, 2E12 viral particles (VP), every two weeks x 4 injections|pembrolizumab, 200 mg, every 3 weeks for up to one year
Pts 1
Age Adult, Older_Adult
Adverse reactions There are not serious adverse reactions caused by oncolytic viru therapy

Relationship Graph

Overview of Knowledge Graph